Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs
Alzamend Neuro (ALZN) reported Q2 2025 financial results, showing significant balance sheet improvements. Net cash from financing activities reached $8.3 million for the six months ended October 31, 2024. Stockholder equity improved to $3.8 million from a deficit of $2.6 million, while cash position strengthened to $4.1 million from $0.4 million.
The company secured financing agreements including a $25 million preferred stock and warrants purchase agreement and a $6.5 million at-the-market sales agreement. These improvements helped regain Nasdaq compliance and prepare for five clinical trials in 2025. The company's lead drug candidate AL001, a novel lithium therapy, is advancing to Phase II trials at Massachusetts General Hospital, while ALZN002, an immunotherapy for Alzheimer's, plans trial resumption in 2025.
Alzamend Neuro (ALZN) ha riportato i risultati finanziari del secondo trimestre del 2025, mostrando significativi miglioramenti nel bilancio. Il flusso di cassa netto dalle attività di finanziamento ha raggiunto 8,3 milioni di dollari per i sei mesi conclusi il 31 ottobre 2024. Il patrimonio netto degli azionisti è migliorato a 3,8 milioni di dollari, rispetto a un deficit di 2,6 milioni di dollari, mentre la posizione di cassa è passata a 4,1 milioni di dollari da 0,4 milioni di dollari.
La società ha assicurato accordi di finanziamento, tra cui un accordo per l'acquisto di azioni privilegiate e warrant da 25 milioni di dollari e un accordo di vendita sul mercato da 6,5 milioni di dollari. Questi miglioramenti hanno aiutato a recuperare la conformità con il Nasdaq e a prepararsi per cinque studi clinici nel 2025. Il principale candidato farmaco dell'azienda, AL001, una nuova terapia al litio, sta avanzando verso la fase II di sperimentazione presso il Massachusetts General Hospital, mentre ALZN002, un'immunoterapia per l'Alzheimer, prevede di riprendere la sperimentazione nel 2025.
Alzamend Neuro (ALZN) presentó los resultados financieros del segundo trimestre de 2025, mostrando mejoras significativas en su balance. El efectivo neto procedente de actividades de financiación alcanzó 8,3 millones de dólares durante los seis meses que finalizaron el 31 de octubre de 2024. El patrimonio de los accionistas mejoró a 3,8 millones de dólares desde un déficit de 2,6 millones de dólares, mientras que la posición de efectivo se fortaleció a 4,1 millones de dólares desde 0,4 millones de dólares.
La compañía aseguró acuerdos de financiación, incluyendo un acuerdo de compra de acciones preferentes y warrants por 25 millones de dólares y un acuerdo de ventas en el mercado por 6,5 millones de dólares. Estas mejoras ayudaron a recuperar el cumplimiento con Nasdaq y a prepararse para cinco ensayos clínicos en 2025. El principal candidato a fármaco de la empresa, AL001, una nueva terapia de litio, avanza a ensayos de fase II en el Massachusetts General Hospital, mientras que ALZN002, una inmunoterapia para el Alzheimer, planea reanudar ensayos en 2025.
알자멘드 뉴로 (ALZN)는 2025년 2분기 재무 결과를 발표하며 재무제표 개선이 두드러진 모습을 보였습니다. 2024년 10월 31일 종료된 6개월 동안 자금 조달 활동에서의 순 현금은 830만 달러에 도달했습니다. 주주 자본은 260만 달러의 적자에서 380만 달러로 개선되었으며, 현금 보유량은 40만 달러에서 410만 달러로 강화되었습니다.
회사는 2500만 달러의 우선주 및 워런트 매입 계약과 650만 달러의 시장 판매 계약을 포함한 자금 조달 계약을 확보했습니다. 이러한 개선은 나스닥 규정을 회복하고 2025년 5건의 임상 시험을 준비하는 데 도움이 되었습니다. 회사의 주요 약물 후보인 AL001은 새로운 리튬 치료제로 메사추세츠 종합병원에서 2상 시험으로 진행되고 있으며, ALZN002는 알츠하이머를 위한 면역 요법으로 2025년에 시험 재개를 계획하고 있습니다.
Alzamend Neuro (ALZN) a publié ses résultats financiers pour le deuxième trimestre 2025, montrant des améliorations significatives de son bilan. Le flux de trésorerie net provenant des activités de financement a atteint 8,3 millions de dollars pour les six mois se terminant le 31 octobre 2024. Les capitaux propres des actionnaires ont amélioré à 3,8 millions de dollars au lieu d'un déficit de 2,6 millions de dollars, tandis que la position de trésorerie s'est renforcée à 4,1 millions de dollars au lieu de 0,4 million de dollars.
L'entreprise a sécurisé des accords de financement, y compris un contrat d'achat d'actions privilégiées et de bons de souscription d'un montant de 25 millions de dollars et un contrat de vente à la marché de 6,5 millions de dollars. Ces améliorations ont contribué à regagner la conformité avec le Nasdaq et à se préparer à cinq essais cliniques en 2025. Le principal candidat médicament de l'entreprise, AL001, une nouvelle thérapie au lithium, avance vers la phase II des essais au Massachusetts General Hospital, tandis qu'ALZN002, une immunothérapie contre Alzheimer, prévoit de reprendre les essais en 2025.
Alzamend Neuro (ALZN) hat die Finanzzahlen für das zweite Quartal 2025 veröffentlicht und dabei signifikante Verbesserungen in der Bilanz gezeigt. Der Nettozufluss aus Finanzierungstätigkeiten belief sich auf 8,3 Millionen Dollar für die sechs Monate bis zum 31. Oktober 2024. Das Eigenkapital der Aktionäre verbesserte sich auf 3,8 Millionen Dollar von einem Defizit von 2,6 Millionen Dollar, während die Liquiditätsposition auf 4,1 Millionen Dollar von 0,4 Millionen Dollar gestärkt wurde.
Das Unternehmen sicherte sich Finanzierungsvereinbarungen, darunter einen 25 Millionen Dollar bevorzugten Aktien- und Warrants-Kaufvertrag sowie einen 6,5 Millionen Dollar Marktverkäufevertrag. Diese Verbesserungen halfen, die Konformität mit der Nasdaq wiederherzustellen und sich auf fünf klinische Studien im Jahr 2025 vorzubereiten. Der Hauptkandidatenwirkstoff AL001, eine neuartige Lithiumtherapie, schreitet in die Phase II-Studien am Massachusetts General Hospital voran, während ALZN002, eine Immuntherapie gegen Alzheimer, eine Wiederaufnahme der Studien im Jahr 2025 plant.
- Net cash from financing activities increased to $8.3 million
- Stockholder equity improved from -$2.6M to $3.8M
- Cash position strengthened from $0.4M to $4.1M
- Total liabilities reduced from $3.2M to $1.3M
- Secured $25M preferred stock purchase agreement
- Regained Nasdaq listing compliance
- Stock performance challenged by market fluctuations
- Clinical trials for ALZN002 suspended, resumption delayed to 2025
Insights
The Q2 financial results show notable improvements in Alzamend's financial position. The company has successfully raised
The secured
The clinical development strategy focuses on AL001, a novel lithium formulation with potentially improved brain penetration and reduced toxicity. The planned five Phase II trials at Massachusetts General Hospital represent an ambitious expansion of the clinical program. The 505(b)(2) pathway could accelerate approval by leveraging existing lithium safety data while demonstrating AL001's advantages.
The diversification into multiple indications (Alzheimer's, bipolar disorder, major depression, PTSD) creates multiple shots on goal, though also increases operational complexity. The temporary pause in ALZN002's immunotherapy program and need for a new CRO suggests some execution challenges that warrant monitoring.
-
During the six months ended October 31, 2024, net cash provided by financing activities was
$8.3 million -
Stockholder equity of
$3.8 million $4.1 million - Strengthened balance sheet in preparation for five clinical trials to be initiated in 2025
-
Net cash provided by financing activities of
$8.3 million -
Stockholder equity of
$3.8 million $2.6 million -
Cash of
$4.1 million $0.4 million -
Total liabilities of
$1.3 million $3.2 million
This year, Alzamend entered into a securities purchase agreement with an institutional investor to purchase up to
“These financing transactions have allowed us to greatly improve our financial situation,” said Stephan Jackman, Chief Executive Officer of Alzamend. “In the first six months of this fiscal year, we have gone from a stockholder deficit to several million in stockholder equity, significantly reduced our outstanding liabilities and increased our cash on hand. These financial improvements allowed us to regain compliance with all applicable requirements for our stock to continue to be listed on Nasdaq and provides us with the capital in preparation of the upcoming clinical trials to be initiated in 2025.”
Strategic Clinical Advancements
Alzamend is developing innovative treatments for Alzheimer’s, BD, MDD and PTSD. Its leading drug candidate, AL001, utilizes a novel lithium-salicylate/L-proline ionic cocrystal to enhance the safety and efficacy of lithium therapy. This improved formulation has shown promise in preclinical studies, demonstrating higher lithium-brain concentrations with reduced toxicity compared to traditional treatments.
Following successful Phase I and IIA trials, AL001 is positioned for five Phase II trials in partnership with Massachusetts General Hospital in 2025. These trials aim to redefine lithium therapy across neurodegenerative and neuropsychiatric conditions by leveraging a lower-dose, high-efficacy approach anticipated to qualify for the
Alzamend’s secondary candidate, ALZN002, is an active immunotherapy aimed at strengthening the ability of a patient’s immunological system to combat Alzheimer’s. The Phase I/IIA trial assesses its safety and efficacy, with trial resumption planned for 2025 following re-engagement of a new clinical research organization.
“We are deeply grateful for the unwavering support of our stockholders and are steadfast in our commitment to maintaining transparency as we drive forward in our mission to deliver breakthrough therapies for the over 43 million Americans affected by Alzheimer’s, BD, MDD, and PTSD,” said Mr. Jackman. “While recent market fluctuations have challenged our stock performance, I am confident that our upcoming studies are set to significantly advance the healthcare industry and enhance stockholder value.”
About Alzamend Neuro
Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s, BD, MDD and PTSD. Our mission is to rapidly develop and market safe and effective treatments. Our current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, salicylate and L-proline, and ALZN002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s. Both of our product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made, and Alzamend undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. More information, including potential risk factors, that could affect Alzamend’s business and financial results are included in Alzamend’s filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20241212522907/en/
Email: Info@Alzamend.com or call: 1-844-722-6333
Source: Alzamend Neuro, Inc.
FAQ
What are ALZN's Q2 2025 financial highlights?
How much funding has ALZN secured in their recent financing agreements?
What clinical trials is ALZN planning for 2025?
How has ALZN's stockholder equity changed from April to October 2024?
What is the status of ALZN's Nasdaq listing compliance?
